Related Experiment Video
Updated: Jan 17, 2026

Optimized Griess Reaction for UV-Vis and Naked-eye Determination of Anti-malarial Primaquine
Published on: October 11, 2019
Assessing ADME gene coverage: An observational study on chloroquine therapy for COVID-19
Nabil Zaid1,2, Lamyaa Benchikhi1, Naoual El Abboudi1
1Higher Institute of Nursing and Health Technical Professions (ISPITS), Rabat - Ministry of Health and Social Protection, Rabat, Morocco.
Selecting the right genotyping and enrichment platforms is key for pharmacogenomic studies. Axiom and SureSelect platforms offer comprehensive coverage for identifying genetic variants, aiding in coronavirus treatment strategies.
Area of Science:
- Genomics
- Pharmacogenomics
- Computational Biology
Background:
- Pharmacogenomic studies are vital for personalized medicine, particularly for understanding drug responses.
- Optimal selection of genotyping and enrichment platforms is crucial for identifying relevant genetic variants.
- This study focuses on identifying genetic variants related to chloroquine efficacy against coronaviruses.
Purpose of the Study:
- To compare various genotyping and enrichment platforms for comprehensive coverage in genome-wide association studies.
- To identify the most effective platforms for targeting new therapeutic approaches against coronaviruses using chloroquine.
- To assess the coverage of absorption, distribution, metabolism, and excretion (ADME) genes.
Main Methods:
- Developed Python scripts to evaluate platform coverage rates for ADME genes.
- Utilized the PLINK tool to assess single nucleotide polymorphisms in linkage disequilibrium with ADME variants.
- Compared coverage across multiple genotyping and enrichment platforms.
Main Results:
- Axiom genotyping and SureSelect enrichment platforms provided the most extensive genomic and pharmacogenomic region coverage.
- These platforms effectively captured a significant proportion of ADME gene variants relevant to chloroquine response.
- Linkage disequilibrium analysis with PLINK indicated extended coverage of relevant genetic variants.
Conclusions:
- Axiom and SureSelect platforms are recommended for pharmacogenomic studies due to their extensive coverage.
- These platforms can aid in discovering new therapeutic targets for coronavirus treatments, including chloroquine.
- The choice of genotyping and enrichment technology significantly impacts the success of pharmacogenomic research.
More Related Videos
10:26Toxicological Assays for Testing Effects of an Epigenetic Drug on Development, Fecundity and Survivorship of Malaria Mosquitoes
Published on: January 16, 2015
09:25CRISPR/Cas9 Gene Editing to Make Conditional Mutants of Human Malaria Parasite P. falciparum
Published on: September 18, 2018
Related Concept Videos
Therapeutic Drug Monitoring: Affecting Factors
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Hepatic Drug Clearance: Effect of Protein Binding
For low-extraction-ratio drugs that are less than 80% protein-bound, minor changes in protein binding...
Measurement of Bioavailability: Pharmacodynamic Methods